A simian immunodeficiency virus V3 loop mutant that does not efficiently use CCR5 or common alternative coreceptors is moderately attenuated in vivo.

[1]  S. Pöhlmann,et al.  Cellular entry of HIV: Evaluation of therapeutic targets. , 2006, Current pharmaceutical design.

[2]  E. Poveda,et al.  HIV entry inhibitors: mechanisms of action and resistance pathways. , 2006, The Journal of antimicrobial chemotherapy.

[3]  I. Markovic.  Advances in HIV-1 entry inhibitors: strategies to interfere with receptor and coreceptor engagement. , 2006, Current pharmaceutical design.

[4]  John P. Moore,et al.  Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor , 2005, Nature Medicine.

[5]  John P. Moore,et al.  Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus–cell fusion , 2005, Nature.

[6]  A. Trkola,et al.  Use of alternate coreceptors on primary cells by two HIV-1 isolates. , 2005, Virology.

[7]  John P. Moore,et al.  Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). , 2005, Virology.

[8]  Mario Roederer,et al.  Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection , 2005, Nature.

[9]  V. Maino,et al.  Insufficient Production and Tissue Delivery of CD4+Memory T Cells in Rapidly Progressive Simian Immunodeficiency Virus Infection , 2004, The Journal of experimental medicine.

[10]  D. Price,et al.  CD4+ T Cell Depletion during all Stages of HIV Disease Occurs Predominantly in the Gastrointestinal Tract , 2004, The Journal of experimental medicine.

[11]  Christine Hogan,et al.  Primary HIV-1 Infection Is Associated with Preferential Depletion of CD4+ T Lymphocytes from Effector Sites in the Gastrointestinal Tract , 2004, The Journal of experimental medicine.

[12]  R. Doms,et al.  Prospects of HIV‐1 entry inhibitors as novel therapeutics , 2004, Reviews in medical virology.

[13]  R. Doms,et al.  Amino Acid 324 in the Simian Immunodeficiency Virus SIVmac V3 Loop Can Confer CD4 Independence and Modulate the Interaction with CCR5 and Alternative Coreceptors , 2004, Journal of Virology.

[14]  Robyn L Stanfield,et al.  Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 Inhibitor , 2004, Journal of Virology.

[15]  John P. Moore,et al.  HIV-1 entry inhibitor entrances. , 2004, Trends in pharmacological sciences.

[16]  R. Doms,et al.  Use of a Small Molecule CCR5 Inhibitor in Macaques to Treat Simian Immunodeficiency Virus Infection or Prevent Simian–Human Immunodeficiency Virus Infection , 2003, The Journal of experimental medicine.

[17]  Y. Endo,et al.  Early Control of Highly Pathogenic Simian Immunodeficiency Virus/Human Immunodeficiency Virus Chimeric Virus Infections in Rhesus Monkeys Usually Results in Long-Lasting Asymptomatic Clinical Outcomes , 2003, Journal of Virology.

[18]  R. Doms,et al.  The entry of entry inhibitors: A fusion of science and medicine , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Overbaugh,et al.  Early- and Intermediate-Stage Variants of Simian Immunodeficiency Virus Replicate Efficiently in Cells Lacking CCR5 , 2003, Journal of Virology.

[20]  Christoph Grundner,et al.  Tyrosine Sulfation of Human Antibodies Contributes to Recognition of the CCR5 Binding Region of HIV-1 gp120 , 2003, Cell.

[21]  J. Bell,et al.  Identification of a Subset of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus Strains Able To Exploit an Alternative Coreceptor on Untransformed Human Brain and Lymphoid Cells , 2003, Journal of Virology.

[22]  J. Kilby,et al.  Novel therapies based on mechanisms of HIV-1 cell entry. , 2003, The New England journal of medicine.

[23]  Á. McKnight,et al.  Cell surface receptors, virus entry and tropism of primate lentiviruses. , 2002, The Journal of general virology.

[24]  A. Trkola,et al.  HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Doms,et al.  Antigenically Distinct Conformations of CXCR4 , 2001, Journal of Virology.

[26]  M. Malim,et al.  Ability of the V3 Loop of Simian Immunodeficiency Virus To Serve as a Target for Antibody-Mediated Neutralization: Correlation of Neutralization Sensitivity, Growth in Macrophages, and Decreased Dependence on CD4 , 2001, Journal of Virology.

[27]  John P. Moore,et al.  Use of Inhibitors To Evaluate Coreceptor Usage by Simian and Simian/Human Immunodeficiency Viruses and Human Immunodeficiency Virus Type 2 in Primary Cells , 2000, Journal of Virology.

[28]  S. O. Smith,et al.  A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Pascal Poignard,et al.  Highly Potent RANTES Analogues either Prevent CCR5-Using Human Immunodeficiency Virus Type 1 Infection In Vivo or Rapidly Select for CXCR4-Using Variants , 1999, Journal of Virology.

[30]  M. Zeitz,et al.  Rapid mucosal CD4(+) T-cell depletion and enteropathy in simian immunodeficiency virus-infected rhesus macaques. , 1999, Gastroenterology.

[31]  H. Guy,et al.  Epitope Mapping of CCR5 Reveals Multiple Conformational States and Distinct but Overlapping Structures Involved in Chemokine and Coreceptor Function* , 1999, The Journal of Biological Chemistry.

[32]  D. Ho,et al.  Natural Infection of a Homozygous Δ24 CCR5 Red-capped Mangabey with an R2b-Tropic Simian Immunodeficiency Virus , 1998, The Journal of experimental medicine.

[33]  P. Marx,et al.  The function of simian chemokine receptors in the replication of SIV. , 1998, Seminars in immunology.

[34]  R P Johnson,et al.  Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. , 1998, Science.

[35]  R. Means,et al.  Simian immunodeficiency virus variants with differential T-cell and macrophage tropism use CCR5 and an unidentified cofactor expressed in CEMx174 cells for efficient entry , 1997, Journal of virology.

[36]  Ying Sun,et al.  Two Orphan Seven-Transmembrane Segment Receptors Which Are Expressed in CD4-positive Cells Support Simian Immunodeficiency Virus Infection , 1997, The Journal of experimental medicine.

[37]  R. Desrosiers,et al.  A role for natural simian immunodeficiency virus and human immunodeficiency virus type 1 nef alleles in lymphocyte activation , 1997, Journal of virology.

[38]  Frank Kirchhoff,et al.  Association of simian immunodeficiency virus Nef with cellular serine/threonine kinases is dispensable for the development of AIDS in rhesus macaques , 1997, Nature Medicine.

[39]  D. Littman,et al.  Expression cloning of new receptors used by simian and human immunodeficiency viruses , 1997, Nature.

[40]  D. Ho,et al.  Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry , 1997, Journal of virology.

[41]  J. Sodroski,et al.  Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239 , 1997, Journal of virology.

[42]  Marc Parmentier,et al.  Regions in β-Chemokine Receptors CCR5 and CCR2b That Determine HIV-1 Cofactor Specificity , 1996, Cell.

[43]  J J Goedert,et al.  Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.

[44]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[45]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[46]  M. Zeitz,et al.  Loss of CD4 T lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood. Berlin Diarrhea/Wasting Syndrome Study Group. , 1995, Gut.

[47]  M. Reitz,et al.  Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1 , 1995, Journal of virology.

[48]  H. Buc,et al.  HIV-1 reverse transcription. A termination step at the center of the genome. , 1994, Journal of molecular biology.

[49]  R. Desrosiers,et al.  The "V3" domain is a determinant of simian immunodeficiency virus cell tropism , 1994, Journal of virology.

[50]  B. Moss,et al.  Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor , 1992, Journal of virology.

[51]  B. Walker,et al.  Techniques in HIV Research , 1990, Palgrave Macmillan UK.

[52]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.

[53]  R. Doms,et al.  Cell-cell fusion assay to study role of chemokine receptors in human immunodeficiency virus type 1 entry. , 1997, Methods in enzymology.